- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07914452
Personalized Routine and Habit Integration to Support Medication Management (PRISM)
A Randomized Controlled Trial of the Personalized Routine and Habit Integration to Support Medication Management Intervention (PRISM)
The objective of this study is to test a multidisciplinary care team behavioral intervention to enhance medication adherence among older adults with multiple chronic conditions (MCC). The Personalized Routine and Habit Integration to Support Medication Management (PRISM) intervention is a novel, scalable intervention delivered by pharmacists and occupational therapists (OTs) that aims to improve medication adherence by reducing regimen complexity and solidifying medication habits within daily routines. The goal of this randomized control trial is to evaluate the effectiveness and implementation of PRISM compared with enhanced usual care.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Julie Lauffenburger, PharmD, PhD
- Phone Number: 857-282-1962
- Email: jlauffenburger@bwh.harvard.edu
Study Locations
-
-
Massachusetts
-
Somerville, Massachusetts, United States, 021250
- Mass General Brigham
-
Contact:
- Julie Lauffenburger, PharmD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- appointment in the past 18 months in the Galter-18 primary care practice
- ≥2 cardiovascular and/or metabolic chronic conditions documented in the EHR,
- ≥5 daily medications
- poor medication adherence ≥1 cardiovascular and/or metabolic medication using validated EHR-data algorithms
- English-speaking
- ≥65 years old
Exclusion Criteria:
- severe mental illness
- dementia
- dependent on others for medication management
- have received a pharmacist-led comprehensive medication review in the last 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: PRISM Arm
The PRISM arm will receive three sessions: 1) comprehensive medication management session with a clinical pharmacist, 2) an in-home visit with an occupational therapist (OT), and then 3) follow up phone call with OT. |
The PRISM arm will receive three sessions: 1) comprehensive medication management session with a clinical pharmacist, 2) an in-home visit with an occupational therapist (OT), and then 3) follow up phone call with OT. |
|
Experimental: Enhanced usual care (EUC) arm
The EUC arm will receive a comprehensive medication management session with a clinical pharmacist. |
The EUC arm will receive a comprehensive medication management session with a clinical pharmacist. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PDC (Continuous) - Cardiometabolic
Time Frame: Through 6-months post-baseline
|
Medication adherence to cardio-metabolic pill-form daily medications including the following classes: ACE inhibitor, Angiotensin Receptor Blockers (ARBs), Beta-Blockers, Calcium Channel Blockers, Diuretics, Lipid-lowering, Metformin |
Through 6-months post-baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
PDC (Continuous) - All
Time Frame: Through 6-months post-baseline
|
Medication adherence to all daily prescription pill-form medications |
Through 6-months post-baseline
|
|
PDC (Continuous) - Study-entering
Time Frame: Through 6-months post-baseline
|
Medication adherence to study-entering medication i.e. the medciation that was identified during the eligibility screening process as having poor medication adherence. |
Through 6-months post-baseline
|
|
Medication Adherence Report Scale 10-item (MARS-10)
Time Frame: Through 3-months post-baseline
|
Self reported; medication ahderence to all prescriptoin daily medications |
Through 3-months post-baseline
|
|
Regimen Knowledge (continuous)
Time Frame: Through 3-months post-baseline
|
Participant knowledge of prescribed medications, including their purpose, dosage, and administration instructions using Medication Purpose & Dosage Identification Score (MPDS). |
Through 3-months post-baseline
|
|
Regimen Complexity (continuous)
Time Frame: Through 3-months post-baseline
|
Complexity of the participant's prescribed medication regime using Medication Regimen Complexity Index (MRCI). |
Through 3-months post-baseline
|
|
Daily Routine (continuous)
Time Frame: Through 3-months post-baseline
|
Daily activity patterns and routines, including the timing of activities throughout the day using a time diary. |
Through 3-months post-baseline
|
|
Medication Habits (continuous)
Time Frame: Through 3-months post-baseline
|
The extent to which medication-taking is performed automatically as a habitual behavior using Self-Report Behavioral Automaticity Index (SRBAI). |
Through 3-months post-baseline
|
|
Problem Solving Skills (continuous)
Time Frame: Through 3-months post-baseline
|
Participant ability to identify, address, and learn from problems affecting medication-taking and health management using Health Problem-Solving Scale (HPSS). |
Through 3-months post-baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2026P001972
- 5P30AG064199-08 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.